Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer-Reference-Cited by-同舟云学术

Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer

Published:2013-12-02 Issue:5 Volume:64 Page:683-692
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Fong Dominic¹²³⁴,Moser Patrizia⁵,Kasal Armin⁶,Seeber Andreas¹²⁴,Gastl Guenther¹²,Martowicz Agnieszka¹²,Wurm Martin¹,Mian Christine⁶,Obrist Peter⁷,Mazzoleni Guido⁶,Spizzo Gilbert¹²³⁴

Affiliation:

1. Tyrolean Cancer Research Institute; Laboratory for Experimental Oncology; Innsbruck Austria

2. Department of Internal Medicine V, Hematology and Oncology; Medical University Innsbruck; Innsbruck Austria

3. Department of Hematology and Oncology; Franz Tappeiner Hospital; Merano Italy

4. Oncotyrol-Center for Personalized Cancer Medicine; Innsbruck Austria

5. Department of Pathology; Medical University Innsbruck; Innsbruck Austria

6. Department of Pathology; Bolzano Regional Hospital; Bolzano Italy

7. Pathology Laboratory Zams; Zams Austria

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.12307/fullpdf

Reference28 articles.

1. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J. Clin. Oncol.,2007

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N. Engl. J. Med.,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Hoff;N. Engl. J. Med.,2013

4. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule;Trzpis;Am. J. Pathol.,2007

5. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis;Spizzo;J. Clin. Pathol.,2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model;Cancer Cell International;2024-06-04

2. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer;Archivum Immunologiae et Therapiae Experimentalis;2023-08-11

3. EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma;Oral Oncology;2023-07

4. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study;Current Medical Science;2023-04-29

5. Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of Anti-Epcam and Anti-VEGFR2 Nanobodies;Current Pharmaceutical Design;2023-04